Join our community
Enclomiphene is an oral selective oestrogen receptor modulator (SERM) being discussed increasingly as a potential treatment for certain men with low testosterone, particularly where maintaining fertility and natural testicular function is important.
Unlike testosterone replacement therapy, enclomiphene does not directly supply testosterone. Instead, it acts on the body's own hypothalamic-pituitary-gonadal axis, increasing the signals that tell the testes to produce testosterone.
However, enclomiphene remains unlicensed in the UK and is not routinely prescribed as part of standard NHS or private testosterone treatment. Current specialist guidance considers it a promising option, but one that requires appropriate clinical assessment and acknowledgement of its unlicensed status.
There is another important distinction that is often overlooked: improving testosterone on a blood test does not automatically mean a patient will feel substantially better. In our experience, some men achieve impressive biochemical results with enclomiphene while seeing relatively little improvement in libido, energy, mood or overall wellbeing.
This guide explains how enclomiphene works, who it may potentially suit, its UK regulatory position, fertility considerations, how it differs from TRT and clomifene, possible side effects, monitoring and what the current clinical evidence actually shows.
Testosterone replacement therapy remains the conventional treatment when a man has clinically significant testosterone deficiency and testosterone replacement is considered appropriate.
Enclomiphene takes a different approach. Rather than replacing testosterone from outside the body, it attempts to stimulate the patient's own hormone-production pathway.
This distinction can make enclomiphene particularly interesting for younger men with secondary hypogonadism, men concerned about fertility or men who would prefer to avoid suppression of LH, FSH and natural testicular testosterone production.
It is not, however, simply an oral version of TRT and it will not be suitable for every type of testosterone deficiency.
The main characteristics that distinguish enclomiphene from conventional testosterone replacement.
An oral selective oestrogen receptor modulator, commonly referred to as a SERM.
Reduces oestrogen-mediated negative feedback and can increase LH and FSH signalling from the pituitary.
Encourages the testes to produce more endogenous testosterone rather than supplying testosterone directly.
Unlike conventional TRT, enclomiphene does not normally suppress LH and FSH and has maintained sperm concentration in clinical studies.
Enclomiphene is currently unlicensed in the UK and is not a routine standard treatment for testosterone deficiency.
Testosterone levels may rise considerably without necessarily producing the same degree of improvement in symptoms.
Enclomiphene citrate is a non-steroidal selective oestrogen receptor modulator. It is the trans-isomer of clomifene citrate, a medicine containing two related isomers: enclomiphene and zuclomiphene.
Enclomiphene has predominantly anti-oestrogenic activity at the hypothalamic-pituitary level. By reducing the negative-feedback signal produced by oestrogen, the brain can increase its output of the gonadotrophins LH and FSH.
LH subsequently stimulates Leydig cells within the testes to produce testosterone, while FSH contributes to Sertoli-cell function and normal sperm production.
The important point is that enclomiphene is attempting to restore endogenous testosterone production rather than replacing testosterone directly.
The effect depends on an intact communication pathway between the brain, pituitary gland and testes.
Oestrogen normally contributes to negative feedback at the hypothalamus and pituitary, helping regulate hormone production.
Enclomiphene antagonises oestrogen receptors involved in this feedback pathway.
Reduced negative feedback can cause the pituitary to increase luteinising hormone and follicle-stimulating hormone.
Where testicular function remains intact, increased LH stimulation can raise endogenous testosterone production.
Enclomiphene relies on the testes being capable of responding to increased stimulation. A higher LH result is of little benefit if the testes themselves cannot produce an adequate amount of testosterone.
Enclomiphene has mainly been investigated in men with secondary or functional hypogonadism.
In secondary hypogonadism, testosterone is low while LH is low or inappropriately normal. The testes may still be capable of producing testosterone but are not receiving sufficient stimulation from the pituitary.
Increasing LH can therefore potentially increase endogenous testosterone production.
Enclomiphene may be of particular interest where fertility remains important, where preserving natural gonadotrophin signalling is a priority, or where a specialist believes stimulation of endogenous testosterone production is preferable to testosterone replacement.
A man with primary testicular failure may already have elevated LH because the pituitary is trying hard to stimulate testes that are not responding adequately.
Raising the stimulation further may therefore provide little benefit.
Enclomiphene should not be viewed simply as an alternative that can replace TRT regardless of the cause of low testosterone.
This is one of the most important points to understand when discussing enclomiphene.
In our experience, some men respond very clearly on paper. Total testosterone may rise, free testosterone may improve and LH and FSH may increase exactly as expected.
Yet despite these objectively better laboratory numbers, some of those patients report surprisingly little change in how they actually feel.
This does not mean that the biochemical response is meaningless. Rather, it demonstrates why testosterone treatment cannot be judged solely by whether a laboratory result reaches a particular number.
The objective of treatment is not simply to produce an attractive testosterone result. A meaningful response should take account of symptoms, function, tolerability, fertility goals and overall wellbeing alongside bloodwork.
Fertility is one of the major reasons enclomiphene has generated interest as an alternative to conventional testosterone replacement.
TRT normally suppresses LH and FSH through negative feedback on the HPG axis. This can substantially reduce intratesticular testosterone and sperm production.
Enclomiphene has the opposite effect on gonadotrophins. Clinical studies have demonstrated increased LH and FSH alongside increased serum testosterone, while sperm concentrations were maintained compared with men receiving testosterone gel.
This makes it potentially attractive for selected men who require treatment for low testosterone but do not want to suppress their reproductive axis.
Maintaining sperm concentration is not the same as guaranteeing fertility, however. Semen analysis remains the appropriate way to assess sperm production, and conception depends on considerably more than testosterone levels alone.
Both approaches may increase serum testosterone, but they achieve this through fundamentally different mechanisms.
Encourages the body's existing HPG axis to increase testicular testosterone production.
Provides testosterone directly through an injectable, transdermal or other prescribed testosterone preparation.
The treatments solve different clinical problems. Their suitability depends on the cause of testosterone deficiency, fertility goals, symptoms, laboratory results, tolerability and the evidence available for the individual patient.
The two medicines are closely related, but they are not identical.
Enclomiphene is the trans-isomer of clomifene and has predominantly anti-oestrogenic activity within the HPG axis.
Research in men has focused on its ability to increase LH, FSH and endogenous testosterone while preserving spermatogenesis.
Clomifene citrate contains both enclomiphene and zuclomiphene. Zuclomiphene has different and more oestrogenic pharmacological characteristics.
Clomifene has licensed indications relating to female fertility, while its use for male hypogonadism is off-label.
Enclomiphene itself does not currently have a UK marketing authorisation and is therefore an unlicensed medicine. Clomifene is a licensed medicine, but using it to treat male testosterone deficiency falls outside its licensed indication and is therefore off-label use.
Enclomiphene is currently unlicensed in the United Kingdom.
This means there is no routinely licensed UK enclomiphene product equivalent to established testosterone medicines such as Testogel, Sustanon, Testosterone Enanthate preparations or Nebido.
An unlicensed medicine can still sometimes be prescribed where an appropriately qualified prescriber considers that there is sufficient clinical justification and takes responsibility for that prescribing decision.
That does not make enclomiphene a routine UK low-testosterone treatment.
Current specialist guidance describes enclomiphene as a promising treatment but does not support treating it as a routine replacement for established testosterone therapies. Where it is prescribed, patients should be appropriately counselled about its unlicensed status and the limitations of the evidence.
Enclomiphene is not part of the conventional testosterone replacement pathway routinely encountered in NHS testosterone treatment.
Where considered, prescribing should involve clinicians experienced in male hypogonadism and the use of unlicensed medicines.
Longer-term information concerning symptom response, safety and fertility outcomes remains more limited than for established TRT.
An internet product labelled “enclomiphene” should not be assumed to contain a pharmaceutical-grade medicine of a known identity, concentration or purity. Unregulated products should not be treated as equivalent to medication supplied through a legitimate prescribing and pharmacy pathway.
Published studies generally report reasonable short-term tolerability, but enclomiphene remains less extensively studied than established testosterone medicines and long-term safety information is limited.
Headaches have been reported during enclomiphene treatment in clinical studies.
Alteration of oestrogen signalling can contribute to flushing or changes in temperature perception.
Gastrointestinal symptoms including nausea have been reported in some patients.
Dizziness has occurred in clinical studies and should be reviewed if persistent or troublesome.
Increasing endogenous testosterone can also increase the amount of testosterone available for conversion into oestradiol.
Rare or longer-term adverse effects are less well characterised because the evidence base remains smaller than for conventional testosterone replacement.
A treatment that raises testosterone still requires appropriate clinical review. Monitoring should assess both what is happening on bloodwork and whether the patient is actually benefiting.
Helps determine the biochemical response to increased endogenous testosterone production.
Can provide useful additional context where total testosterone alone does not explain the clinical picture.
These markers help demonstrate whether the expected pituitary response to treatment is occurring.
Increasing endogenous testosterone production can also influence circulating oestradiol.
Libido, energy, mood, cognition, sexual function and overall wellbeing should be considered alongside laboratory values.
Semen analysis provides considerably more useful fertility information than assuming fertility has been maintained because LH and FSH remain measurable.
The existing literature provides encouraging evidence for increasing testosterone while maintaining gonadotrophin and sperm production, but the strengths and limitations of that evidence need to be kept in perspective.
Clinical research found that enclomiphene increased total testosterone in men with secondary hypogonadism while simultaneously increasing LH and FSH, in contrast with testosterone gel, which suppressed gonadotrophins.
View StudyAnother randomised trial reported increased testosterone while sperm counts were conserved with enclomiphene, unlike topical testosterone treatment.
View StudyTwo multicentre phase III studies found increases in testosterone, LH and FSH with enclomiphene while sperm concentrations remained in the normal range during the treatment period.
View StudyCurrent UK specialist discussion recognises enclomiphene as a potentially useful treatment capable of increasing testosterone while maintaining gonadotrophin signalling and spermatogenesis.
However, existing research remains considerably more limited than the evidence available for established testosterone replacement therapies, particularly when considering long-term symptom response, safety and fertility outcomes.
Enclomiphene should therefore be regarded as a specialist and currently unlicensed treatment rather than a routine substitute for established TRT.
Read the BSSM Position StatementMuch of the enclomiphene literature has concentrated on testosterone, LH, FSH and semen parameters. These are important outcomes, but long-term symptom relief, quality of life and comparative clinical outcomes remain less comprehensively established than the biochemical effect.
Explore testosterone treatment, fertility, hCG, blood testing and other options used within UK hormone care.
Common questions about enclomiphene, low testosterone, fertility and its current status in the UK.
No. Enclomiphene is currently an unlicensed medicine in the UK. It may be considered in selected circumstances by appropriately experienced clinicians, but it is not a routinely licensed treatment for testosterone deficiency.
No. Enclomiphene remains relatively uncommon in UK testosterone treatment. Its unlicensed status, specialist prescribing requirements and more limited long-term evidence mean that conventional testosterone replacement remains much more commonly encountered.
No. TRT supplies testosterone directly. Enclomiphene instead stimulates the body's HPG axis, increasing LH and FSH so that the testes may produce more testosterone naturally.
It has principally been investigated in men with secondary hypogonadism, where testosterone is low but the testes remain capable of responding to increased LH stimulation.
Clinical studies have demonstrated significant increases in total testosterone together with increases in LH and FSH in men with secondary hypogonadism.
Yes. Biochemical and symptomatic responses are not necessarily identical. In our experience, some men achieve substantial improvements in testosterone results while reporting much less improvement in energy, libido, mood or general wellbeing.
Clinical trials have shown preservation of sperm concentration during enclomiphene treatment compared with testosterone gel. However, this should not be interpreted as a guarantee of fertility for every individual.
Generally the opposite occurs. Enclomiphene reduces oestrogen-mediated negative feedback and has been shown to increase LH and FSH in clinical studies.
Enclomiphene is one of the two isomers contained within clomifene. Clomifene contains both enclomiphene and zuclomiphene, which have different pharmacological properties.
Enclomiphene itself is unlicensed in the UK because it does not currently have a UK marketing authorisation. Off-label use describes a licensed medicine being prescribed outside the terms of its licence.
Clinical research has demonstrated measurable increases in testosterone within the first few weeks of treatment. The timing and extent of both biochemical and symptomatic response vary between individuals.
Products marketed directly online should not be assumed to be legitimate pharmaceutical enclomiphene. An unregulated product may have uncertain identity, concentration, purity or quality. Prescription treatment should be managed through an appropriate clinician and pharmacy pathway.
This guide is provided for general educational purposes and does not replace personalised medical advice, diagnosis or treatment. Enclomiphene is currently an unlicensed medicine in the UK. Decisions concerning testosterone deficiency, fertility and prescription treatment should be made with an appropriately qualified healthcare professional.
